Tag Archives: Soumit Roy

Surface Oncology (SURF) Gets a Buy Rating from JonesTrading

JonesTrading analyst Soumit Roy reiterated a Buy rating on Surface Oncology (SURF – Research Report) today and set a price target of $12.00. The company’s shares closed last Monday at $1.63, close to its 52-week low of $1.15. According to

JonesTrading Keeps Their Buy Rating on Celyad (CYAD)

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Celyad (CYAD – Research Report), with a price target of $60.00. The company’s shares closed last Monday at $8.88, close to its 52-week low of $8.10.

JonesTrading Reaffirms Their Buy Rating on Neon Therapeutics (NTGN)

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Neon Therapeutics (NTGN – Research Report), with a price target of $30.00. The company’s shares closed last Monday at $2.00, close to its 52-week low of

Analysts Offer Insights on Healthcare Companies: Infinity Pharma (NASDAQ: INFI) and Myovant Sciences (NYSE: MYOV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Infinity Pharma (INFI – Research Report) and Myovant Sciences (MYOV – Research Report) with bullish sentiments. Infinity Pharma (INFI) JonesTrading analyst Soumit

JonesTrading Sticks to Its Buy Rating for Aeglea Biotherapeutics Inc (AGLE)

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Aeglea Biotherapeutics Inc (AGLE – Research Report), with a price target of $16. The company’s shares closed last Monday at $7.72. Roy wrote: “Aegl ea ’s

JonesTrading Sticks to Their Buy Rating for Forty Seven Inc (FTSV)

JonesTrading analyst Soumit Roy reiterated a Buy rating on Forty Seven Inc (FTSV – Research Report) yesterday. The company’s shares closed last Monday at $6.66, close to its 52-week low of $6.21. Roy wrote: “Forty Seven’s earnings updates indicated key